[1]
Tfelt-Hansen P, Saxena PR, Dahlöf C, Pascual J, Láinez M, Henry P, Diener H, Schoenen J, Ferrari MD, Goadsby PJ. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain : a journal of neurology. 2000 Jan:123 ( Pt 1)():9-18
[PubMed PMID: 10611116]
Level 3 (low-level) evidence
[2]
. Migraine Headache Agents. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():
[PubMed PMID: 31643527]
[3]
Arnold AC, Ramirez CE, Choi L, Okamoto LE, Gamboa A, Diedrich A, Raj SR, Robertson D, Biaggioni I, Shibao CA. Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure. Frontiers in physiology. 2014:5():270. doi: 10.3389/fphys.2014.00270. Epub 2014 Jul 24
[PubMed PMID: 25104940]
[4]
Hou M, Xing H, Cai Y, Li B, Wang X, Li P, Hu X, Chen J. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. The journal of headache and pain. 2017 Dec:18(1):42. doi: 10.1186/s10194-017-0750-1. Epub 2017 Apr 7
[PubMed PMID: 28389966]
Level 1 (high-level) evidence
[5]
Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 Feb:43(2):144-66
[PubMed PMID: 12558771]
[6]
Anderson JR, Drehsen G, Pitman IH. Effect of caffeine on ergotamine absorption from rat small intestine. Journal of pharmaceutical sciences. 1981 Jun:70(6):651-7
[PubMed PMID: 7252810]
[7]
Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ, Eletriptan and Cafergot Comparative Study Group. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. European neurology. 2002:47(2):99-107
[PubMed PMID: 11844898]
Level 1 (high-level) evidence
[8]
Lipton RB, Diener HC, Robbins MS, Garas SY, Patel K. Caffeine in the management of patients with headache. The journal of headache and pain. 2017 Oct 24:18(1):107. doi: 10.1186/s10194-017-0806-2. Epub 2017 Oct 24
[PubMed PMID: 29067618]
[10]
Mathew NT. Dosing and administration of ergotamine tartrate and dihydroergotamine. Headache. 1997:37 Suppl 1():S26-32
[PubMed PMID: 9009471]
[11]
Ekbom K, Krabbe AE, Paalzow G, Paalzow L, Tfelt-Hansen P, Waldenlind E. Optimal routes of administration of ergotamine tartrate in cluster headache patients. A pharmacokinetic study. Cephalalgia : an international journal of headache. 1983 Mar:3(1):15-20
[PubMed PMID: 6406071]
[12]
Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. SpringerPlus. 2016:5():637. doi: 10.1186/s40064-016-2211-8. Epub 2016 May 17
[PubMed PMID: 27330903]
Level 3 (low-level) evidence
[13]
Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache. 1997:37 Suppl 1():S33-41
[PubMed PMID: 9009472]
[14]
Bocchia M, Baldini GG, Bertola G, Zorzoli C. [Risks related to the use of ergotamine in the therapy of hemicrania. Description of a case]. Recenti progressi in medicina. 1991 Jul-Aug:82(7-8):390-3
[PubMed PMID: 1947404]
Level 3 (low-level) evidence
[15]
Aabech J, Jensen FB, Engell HC. [Ergotism in migraine. Peripheral vascular complications in 14 patients with migraine]. Ugeskrift for laeger. 1989 Aug 14:151(33):2067-70
[PubMed PMID: 2773132]
[16]
Jost WH, Schimrigk K. [Ergotamine-induced rectal lesions in asymptomatic patients]. Wiener klinische Wochenschrift. 1994:106(6):171-3
[PubMed PMID: 8197748]
[17]
Meyler WJ. Side effects of ergotamine. Cephalalgia : an international journal of headache. 1996 Feb:16(1):5-10
[PubMed PMID: 8825693]
[18]
Pérez Baztarrica GE, Armijos Carrion LP, Abarca Real JH, Paredes Lima WA, Giler Saltos OP, Porcile R. Acute coronary syndrome with elevation of ST associated with ergotamine abuse. Romanian journal of internal medicine = Revue roumaine de medecine interne. 2019 Mar 1:57(1):69-71. doi: 10.2478/rjim-2018-0023. Epub
[PubMed PMID: 30954974]
[19]
Wooltorton E. Risk of stroke, gangrene from ergot drug interactions. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2003 Apr 15:168(8):1015
[PubMed PMID: 12695387]
[20]
Wells KE, Steed DL, Zajko AB, Webster MW. Recognition and treatment of arterial insufficiency from cafergot. Journal of vascular surgery. 1986 Jul:4(1):8-15
[PubMed PMID: 3723691]
[21]
Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. British journal of clinical pharmacology. 1983 Dec:16(6):695-9
[PubMed PMID: 6419759]
[22]
Skowronski GA,Tronson MD,Parkin WG, Successful treatment of ergotamine poisoning with sodium nitroprusside. The Medical journal of Australia. 1979 Jul 14;
[PubMed PMID: 502953]
[24]
Miljković S, Smajlović D, Tirić Campara M, Jurina R, Duranović Vinković L, Janković SM, Begović B, Ćeranić M. The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura. Hippokratia. 2018 Jan-Mar:22(1):17-22
[PubMed PMID: 31213753]
Level 2 (mid-level) evidence
[25]
Demaagd G. The pharmacological management of migraine, part 1: overview and abortive therapy. P & T : a peer-reviewed journal for formulary management. 2008 Jul:33(7):404-16
[PubMed PMID: 19750119]
Level 3 (low-level) evidence
[26]
Öztürk V. Acute Treatment of Migraine. Noro psikiyatri arsivi. 2013 Aug:50(Suppl 1):S26-S29. doi: 10.4274/Npa.y7299. Epub 2013 Aug 1
[PubMed PMID: 28360580]
[27]
Larsson B, Carlsson J, Fichtel A, Melin L. Relaxation treatment of adolescent headache sufferers: results from a school-based replication series. Headache. 2005 Jun:45(6):692-704
[PubMed PMID: 15953302]
[28]
Gaul C, Visscher CM, Bhola R, Sorbi MJ, Galli F, Rasmussen AV, Jensen R. Team players against headache: multidisciplinary treatment of primary headaches and medication overuse headache. The journal of headache and pain. 2011 Oct:12(5):511-9. doi: 10.1007/s10194-011-0364-y. Epub 2011 Jul 21
[PubMed PMID: 21779789]